Delta 9 Reports Revenue for Q2 2019

Published: August 29, 2019

Delta 9 Reports Revenue for Q2 2019

Delta 9 Cannabis Inc. have announced financial and operating results for the second quarter of 2019.

Financial Highlights for Q2, 2019

  • Record operating revenues of $8.9 million for the second quarter of 2019, up 1,142%, from $715,746 for the same quarter last year.
    • Sequential net revenues increased 58% for the second quarter of 2019 compared to $5,632,184 in Q1, 2019.
  • Adjusted EBITDA1 was $(663,705) up $1.3 million or 65% compared to $(1,978,778) in Q1, 2019.
  • Gross profitof $2.9 million for the second quarter of 2019, up 780%, from $335,226 for the same quarter last year.
    • Gross profit margin was 33% for Q2, 2019.

“Management would highlight the improvement of $1.3 million in Adjusted EBITDA loss over the past two quarters as a positive indication of the performance of the Company’s operating businesses in the wake of legalization of recreational use cannabis on October 17, 2018,” said John Arbuthnot, CEO of Delta 9. “We believe our Q2 results demonstrate the continued strength of our business model as we pursue a path towards profitability and disciplined growth for this year.”

Financial Highlights for the first half of 2019

  • Record operating revenues of $14.5 million, up 1,286%, from $1.0 million for the same period last year.
  • Gross profit2 of $4.8 million, up 973%, from $444164 for the same period last year.
    • Gross profit margin was 33% for the first half of 2019.

“Delta 9 will continue to drive sustainable long-term shareholder value by leveraging its strong brand positioning in Western Canadian markets, expanding our various wholesale supply contracts and scaling up our cultivation operations said John Arbuthnot,” CEO of Delta 9. “We are taking a responsible and compliant approach to growing our business to build an authentic Delta 9 brand as we pursue retail opportunities in the Western Canadian market place.”

Operational Highlights

  • On May 20, 2019, the Company received approval from Health Canada for an additional 48 of its proprietary “Grow Pods”, bringing its total number of Grow Pods approved by Health Canada to 202.
    • The additional 48 Grow Pods will increase production by 1,150 kilograms per year of dried cannabis flower production, bringing the Company’s overall anticipated production capacity to 5,350 kilograms of dried cannabis flower per year.
  • There are now a total of 297 Grow Pods within its Winnipeg production facility (the “Delta Facility”).
  • The Company is continuing with its planned Phase II expansion of the Delta Facility to increase cannabis production to 16,500 kilograms per year.

“The 297 Grow Pods that Delta 9 now has in in our production facility will bring our anticipated production capacity to 7,626 kilograms once all the pods are approved by Health Canada for production,” said John Arbuthnot, CEO of Delta 9.

Selected Quarterly Information:

Consolidated Statement of Net Income

Q2 2019

Q2 2018

Revenue

$8,886,155

$715,746

Cost of Sales

5,936,975

380,520

Gross Profit Before Unrealized Gain from Changes In Biological Assets

2,949,180

335,226

Unrealized gain from changes in fair value of biological assets

4,378,353

328,214

Gross Profit

$3,535,546

$663,440

Expenses

General and Administrative

3,075,803

2,056,097

Sales and Marketing

1,324,537

265,332

Share based Compensation

244,848

521,598

Total Operating Expenses

$4,645,188

$2,843,027

Loss from Operations

$(1,109,642)

$(2,179,587)

Other Income/ Expenses

Finance Income (cost)

(217,975)

(7,172)

Rental and other income

11,744

3,750

Net Income

$1,315,873

$(2,183,009)

Other comprehensive Income

Fair value change in West leaf Investment

(9,240,000)

Net Income and Comprehensive Income

$(10,555,873)

$(2,183,009)

Earnings per Share (basic)

$(0.01)

$(0.03)

Weighted average number of shares outstanding

87,713,479

86,759,632

“Additionally, Delta 9 is looking forward to being up listed on the Toronto Stock Exchange,” said John Arbuthnot, CEO of Delta 9. “This will be a major milestone for the evolution of our company and should enhance the financial opportunities for our shareholders.”

Consolidated Statement of Net Loss

Q2 2019

Q1 2019

Q4 2018

Q3 2018

Revenue

$8,886,155

$5,632,184

$5,270,217

$1,251,213

Cost of Sales

$5,936,975

$3,815,930

$4,015,644

$938,733

Gross Profit Before Unrealized Gain from Changes In Biological Assets

$2,949,180

$1,816,254

$1,254,573

$312,480

Unrealized gain from changes in fair value of biological assets

$586,366

$2,406,735

$2,087,367

$1,218,257

Gross Profit (Loss)

$3,535,546

$4,222,989

$3,341,940

$1,530,737

Expenses

General and Administrative

$3,075,803

$3,451,900

$3,296,351

$2,790,227

Sales and Marketing

$1,324,537

$969,202

$1,389,241

$300,138

Share Based Compensation

$244,848

$748,067

$807,834

$671,606

Total Operating Expenses

$4,645,188

$5,169,169

$5,493,426

$3,761,971

Adjusted EBITDA (Loss)

$(663,705)

$(1,978,778)

$(2,815,412)

$(2,584,485)

Income (Loss) from Operations

$(1,109,642)

$(946,180)

$(2,151,486)

$(2,231,234)

Other Income/ Expenses

$(206,231)

$17,260,525

$69,033

$(164,075)

Net Income (Loss)

$(1,315,873)

$16,314,345

$(2,082,453)

$(2,395,309)

Basic and Diluted Earnings (Loss) Per Share

$(0.01)

$0.19

$(0.02)

$(0.03)

The following chart provides a breakdown of the Company’s revenue by segment:

Revenue from the Sale of Cannabis

Six-month
period ending
June 30, 2019

Six-month
period ending
June 30, 2018

Three-month
period ending
June 30, 2019

Three-month
period ending
March 31, 2019

Wholesale Cannabis Revenue

$5,853,288

$2,917,647

$2,935,641

Retail Cannabis Revenue

5,956,500

3,519,406

2,437,094

Medicinal Cannabis Revenue

183,976

445,176

87,416

96,560

Revenue from Other categories

Business to business activities

2,210,167

502,634

2,165,167

45,000

Merchandise and cannabis devices

339,235

22,985

184,164

155,071

Other

109,713

77,058

62,976

46,737

Sub total

$14,652,879

$1,047,853

$8,936,776

$5,716,103

(Less) Excise Taxes

134,540

0

50,621

83,919

Net Revenue

$14,518,339

$1,047,853

$8,886,155

$5,632,184

Discussion of Operations for Q2 versus Q1, 2019: 

Key Performance Indicators

For the three-month period
ending March 31, 2019

For the three-month period
ending June 30, 2019

Production/ Wholesale Unit

Total Grams Produced

418,901

675,233

Direct Production Cost Per Gram

$1.44

$1.05

Total Cost Per Gram

$1.60

$1.21

Total Grams Released for Sale

185,626

565,599

Total Grams Sold (Recreational Wholesale)

386,387

517,718

Total Grams Sold (Medical)

13,400

9,975

Avg Selling Price per Gram

$7.58

$5.63

Retail Unit

Total Grams Sold (Retail)

189,796

282,336

Avg Selling Price per Gram

$12.84

$12.42

Number of Transactions Processed

44,885

84,882

Avg Transaction Size

$58.27

$41.46

Unique Website Visitors (delta9.ca)

180,774

152,680

A comprehensive discussion of Delta 9’s financial position and results of operations is provided in the Company’s Management Discussion & Analysis for the second quarter and first half of 2019 filed on SEDAR and can be found at www.sedar.com.

Q2 Results 2019 Conference Call

Delta 9 has scheduled a conference call to discuss the results for second quarter of 2019. The conference call will be hosted August 28, 2019 at 9:00 a.m. Eastern Time by John Arbuthnot, Chief Executive Officer and Jim Lawson, Chief Financial Officer, followed by a question and answer period.

DATE:

August 28, 2019

TIME:

9:00 a.m. Eastern Time

DIAL IN #

1-888-886-7786

REPLAY:

1-877-674-6060
Available until 12:00 midnight Eastern Time, November 28, 2019

REPLAY PASSCODE:

528211 #

Delta 9 Cannabis Inc. is a vertically integrated cannabis company focused on bringing the highest quality cannabis products to market. Delta 9’s wholly-owned subsidiary, Delta 9 Bio-Tech Inc., is a licensed producer of medical and recreational cannabis and operates an 80,000 square foot production facility in Winnipeg, Manitoba, Canada.